Global Onychomycosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Onychomycosis Treatment Market is presumed to reach the market size of nearly USD 9.56 Billion by 2032 from USD 5.58 Billion in 2023 with a CAGR of 6.16% under the study period 2024-2032.

Onychomycosis is a kind of fungal infection of fingernails and toenails in which the nails appear to be discolored, thickened, and separated from the nail bed. It may involve any nail component such as a nail plate, nail matrix, and nail bed. This condition is also known as tinea unguium or dermatophytic onychomycosis. The three main types of fungi responsible for causing onychomycosis are yeasts, dermatophytes, and non dermatophyte molds. Onychomycosis can be treated both topically and orally. A combination of oral and topical treatment is expected to show effective results. The most effective onychomycosis treatment available is systemic antifungal agents, but the cure rate is far below 100%, and it may recur even after treatment. The disease can also be treated with laser therapy and photodynamic therapy. However, curing onychomycosis involves a longer treatment duration.

MARKET DYNAMICS

The onychomycosis treatment market shows promising growth opportunities in the coming years. The key factors driving the market are the growing prevalence of chronic diseases like diabetes mellitus, psoriasis, and peripheral vascular disease and a rise in the number of senior population across the globe. People suffering from diabetes mellitus are 1.9 to 2.8 more prone to onychomycosis. The fact that dermatologists and podiatrists are becoming more aware of onychomycosis therapeutics and the growing trend among individuals to maintain the aesthetic appeal of the nails. The onychomycosis treatment market will also be favored by increasing onychomycosis incidence among athletes owing to nail sweating, constant use of shoes, and nail injuries. Other factors contributing to the market growth are changing lifestyles that include activities such as using gyms and public swimming pools. Furthermore, adopting novel drugs for treating the disease, a surge in onychomycosis treatment product sale through online stores, and strategic partnerships, mergers, and collaborations by market players will propel market growth. However, side-effects related to onychomycosis treatment drugs and lack of awareness about onychomycosis may limit the onychomycosis treatment market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Onychomycosis Treatment. The growth and trends of Onychomycosis Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Onychomycosis Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Distal Subungual Onychomycosis (DSO)
White Superficial Onychomycosis (WSO)
Proximal Subungual Onychomycosis (PSO)
Candida Onychomycosis
Others

By Treatment Type

Drug Treatment
Topical Therapy

By Drug Class

Allylamine
Azole
Griseofulvin
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Onychomycosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Onychomycosis Treatment market include Pfizer Inc., Novartis AG, Johnson & Johnson Services Inc., Medimetriks Pharmaceuticals Inc., Bausch Health Sciences, Galderma Laboratories, Moberg Pharma AB, Dr. Reddy'S Laboratories Ltd, Merz Pharma, Kaken Pharmaceutical Co. Ltd, GlaxoSmithKline Plc, Taro Pharmaceuticals Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11215983

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ONYCHOMYCOSIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Treatment Type
- 3.7.3 Market Attractiveness Analysis By Drug Class
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Distal Subungual Onychomycosis (DSO) Historic and Forecast Sales By Regions
5.4. White Superficial Onychomycosis (WSO) Historic and Forecast Sales By Regions
5.5. Proximal Subungual Onychomycosis (PSO) Historic and Forecast Sales By Regions
5.6. Candida Onychomycosis Historic and Forecast Sales By Regions
5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

6.1. Overview By Treatment Type
6.2. Historical and Forecast Data Analysis By Treatment Type
6.3. Drug Treatment Historic and Forecast Sales By Regions
6.4. Topical Therapy Historic and Forecast Sales By Regions

7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

7.1. Overview By Drug Class
7.2. Historical and Forecast Data Analysis By Drug Class
7.3. Allylamine Historic and Forecast Sales By Regions
7.4. Azole Historic and Forecast Sales By Regions
7.5. Griseofulvin Historic and Forecast Sales By Regions
7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data Analysis By Distribution Channel
8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
8.4. Retail Pharmacies Historic and Forecast Sales By Regions
8.5. Online Pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ONYCHOMYCOSIS TREATMENT COMPANIES

10.1. Onychomycosis Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF ONYCHOMYCOSIS TREATMENT INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Pfizer Inc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Novartis AG
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Johnson & Johnson Services Inc.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Medimetriks Pharmaceuticals Inc.
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Bausch Health Sciences
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Galderma Laboratories
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Moberg Pharma AB
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Dr. Reddy'S Laboratories Ltd
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Merz Pharma
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Kaken Pharmaceutical Co. Ltd
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. GlaxoSmithKline Plc
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments
11.14. Taro Pharmaceuticals Industries Ltd
- 11.14.1 Company Overview
- 11.14.2 Company Revenue
- 11.14.3 Products
- 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies